S. Karger AG

SHERPA: Unknown

People

  1. Chi
    Chi
  2. D'Angelo
    D'Angelo
  3. Tap
    Tap
  4. Schoenfeld
    Schoenfeld
  5. Antonescu
    Antonescu
  6. Crago
    Crago
  7. Dickson
    Dickson
  8. Gounder
    Gounder
  9. Keohan
    Keohan
  10. Landa
    Landa

Groups

  1. Department of Medicine (8)
  2. Sarcoma Service (8)
  3. Solid Tumor Oncology Division (8)
  4. GSK Faculty (4)
  5. Tow Center for Developmental Oncology (TCDO) (4)
  6. Hematologic Malignancies, Division of (3)
  7. Human Oncology and Pathogenesis Program (3)
  8. Thoracic Oncology (2)
  9. Weinberg Fellows (2)
  10. Body Imaging Service (1)
Search Within
  1. "Sarcoma Service"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (1)
Groups
  1. Department of Medicine (8)
  2. Sarcoma Service (8)
  3. Solid Tumor Oncology Division (8)
  4. GSK Faculty (4)
  5. Tow Center for Developmental Oncology (TCDO) (4)
  6. Hematologic Malignancies, Division of (3)

More Groups

People
  1. Ping Chi (3)
  2. Sandra D'Angelo (3)
  3. William Tap (3)
  4. Adam Schoenfeld (2)
  5. Aimee Crago (1)
  6. Cristina Antonescu (1)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (1)
  5. 2016 (1)
  6. 2015 (1)
Publications
  1. Oncology Research and Treatment (7)
  2. Oncology (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors: analyses from INVICTUS
    Meeting Abstract

    Bauer, S.; Heinrich, M. C.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
    Meeting Abstract

    Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Meeting Abstract

    Bauer, S.; Heinrich, M.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Long-term efficacy, tolerability, and overall survival in patients with unresectable or metastatic platelet-derived growth factor receptor A (PDGFRA) D842V-mutant gastrointestinal stromal tumors (GIST) treated with avapritinib: NAVIGATOR phase 1 trial update
    Meeting Abstract

    Bauer, S.; Serrano, C.; von Mehren, M.; George, S.; Heinrich, M. C.; Kang, Y. K.; Schöffski, P.; Cassier, P. A.; Mir, O.; Eskens, F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (Dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts)
    Meeting Abstract

    Tap, W.; Jones, R. L.; Chmelowski, B.; Elias, A. A.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Outcomes of systemic therapy for patients with metastatic angiosarcoma
    Journal Article

    D'Angelo, S. P.; Munhoz, R. R.; Kuk, D.; Landa, J.; Hartley, E. W.; Bonafede, M.; Dickson, M. A.; Gounder, M.; Keohan, M. L.; Crago, A. M.; more...
    Oncology (2015)

    Fulltext@MSK | Save